Lumos Pharma (LUMO) Stock Price, News & Analysis

Company Overview

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.

Key Stats

• Today's Range: $4.32 to $4.34
• 50-Day Range: $3.54 to $4.45
• 52-Week Range: $1.37 to $4.58
• Volume: 84,439 shs
• Average Volume: 136,808 shs
• Market Capitalization: $37.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.63
• Consensus Rating: Buy

Lumos Pharma Stock Analysis - MarketRank™

Lumos Pharma scored higher than 64% of companies evaluated by MarketBeat, and ranked 387th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Lumos Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Lumos Pharma has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Lumos Pharma are expected to grow in the coming year, from ($2.32) to ($1.53) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lumos Pharma is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lumos Pharma is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lumos Pharma has a P/B Ratio of 7.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.54% of the float of Lumos Pharma has been sold short.

Short Interest Ratio / Days to Cover

Lumos Pharma has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lumos Pharma has recently decreased by 69.73%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lumos Pharma does not currently pay a dividend.

Dividend Growth

Lumos Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.54% of the float of Lumos Pharma has been sold short.

Short Interest Ratio / Days to Cover

Lumos Pharma has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lumos Pharma has recently decreased by 69.73%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lumos Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

25.40% of the stock of Lumos Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 33.99% of the stock of Lumos Pharma is held by institutions.

LUMO Stock Analysis - Frequently Asked Questions

How have LUMO shares performed this year?

Lumos Pharma's stock was trading at $3.18 at the beginning of 2024. Since then, LUMO shares have increased by 35.8% and is now trading at $4.32.
View the best growth stocks for 2024 here.

How were Lumos Pharma's earnings last quarter?

Lumos Pharma, Inc. (NASDAQ:LUMO) posted its earnings results on Thursday, August, 1st. The company reported ($0.93) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.26) by $0.33. The company earned $0.49 million during the quarter. Lumos Pharma had a negative net margin of 1,583.49% and a negative trailing twelve-month return on equity of 233.03%.

Who are Lumos Pharma's major shareholders?

Top institutional investors of Lumos Pharma include Private Advisor Group LLC (9.17%). Insiders that own company stock include John C Mckew, Thomas A Raffin and Richard J Hawkins.
View institutional ownership trends.

How do I buy shares of Lumos Pharma?

Shares of LUMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Lumos Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lumos Pharma investors own include uniQure (QURE), Clean Energy Fuels (CLNE), ACADIA Pharmaceuticals (ACAD), Bicycle Therapeutics (BCYC), Curaleaf (CURLF), Paycom Software (PAYC) and Vale (VALE).

Company Calendar

• Last Earnings: 8/01/2024
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/06/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LUMO
• CUSIP: N/A
• CIK: 1126234
• Web: www.lumos-pharma.com
• Phone: (512) 215-2630
• Fax: 515-296-3520
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.63
• High Stock Price Target: $13.00
• Low Stock Price Target: $4.25
• Potential Upside/Downside: +99.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($4.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-34,030,000.00
• Net Margins: -1,583.49%
• Pretax Margin: -1,583.49%
• Return on Equity: -233.03%
• Return on Assets: -129.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.66
• Quick Ratio: 2.66

Sales & Book Value

• Annual Sales: $2.05 million
• Price / Sales: 18.23
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.57 per share
• Price / Book: 7.58

Miscellaneous

• Outstanding Shares: 8,650,000
• Free Float: 6,452,000
• Market Cap: $37.37 million
• Optionable: Not Optionable
• Beta: 0.76